Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Key Points

• Acumen Pharmaceuticals reported a quarterly loss of $0.45 per share, missing analysts’ consensus estimate of a $0.36 loss by $0.09.
• The company continues to target late 2026 for top-line Phase II ALTITUDE-AD results for sabirnetug and plans to file an IND for a blood-brain-barrier delivery candidate in mid-2027.
• Acumen ended the quarter with $110.2 million in cash and marketable securities, which management expects will fund operations only into early 2027, while reporting a $32.7 million net loss.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.09), FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals' conference call:

• Acumen continues to expect top-line Phase II ALTITUDE-AD results in late 2026 for sabirnetug, including clinical efficacy, safety, ARIA rates, and fluid and imaging biomarker data.
• The company nominated two blood-brain-barrier delivery candidates, ACU301 and ACU401, with ACU401 showing up to 40-fold greater frontal-cortex exposure in non-human primates; Acumen expects to file an IND for a lead candidate in mid-2027.
• Management believes sabirnetug’s oligomer selectivity and IgG2 antibody design could provide a differentiated safety and tolerability profile versus plaque-targeting IgG1 therapies, though this remains to be demonstrated in the Phase II readout.
• Acumen ended the quarter with $110.2 million in cash and marketable securities, expected to fund operations only into early 2027, while reporting a second-quarter net loss of $32.7 million.

Acumen Pharmaceuticals Stock Performance

Shares of Acumen Pharmaceuticals stock traded up $0.06 during trading on Wednesday, reaching $2.53. The company's stock had a trading volume of 291,069 shares, compared to its average volume of 594,859. The company has a 50-day moving average price of $2.36 and a two-hundred day moving average price of $2.54. The firm has a market cap of $182.74 million, a PE ratio of -1.36 and a beta of 0.36. Acumen Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $3.60. The company has a current ratio of 4.55, a quick ratio of 4.55 and a debt-to-equity ratio of 0.19.

Insider Buying and Selling

In related news, Director Derrell Porter sold 13,040 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $2.33, for a total transaction of $30,383.20. Following the completion of the sale, the director owned 35,500 shares in the company, valued at $82,715. This represents a 26.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 38,700 shares of company stock valued at $89,660. 10.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC purchased a new position in shares of Acumen Pharmaceuticals during the first quarter worth about $46,000. Marshall Wace LLP acquired a new stake in Acumen Pharmaceuticals during the 2nd quarter worth approximately $160,000. Qube Research & Technologies Ltd grew its stake in shares of Acumen Pharmaceuticals by 160.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company's stock valued at $67,000 after purchasing an additional 35,424 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Acumen Pharmaceuticals by 1,526.0% in the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company's stock valued at $204,000 after purchasing an additional 164,866 shares during the last quarter. Finally, Hudson Bay Capital Management LP increased its holdings in shares of Acumen Pharmaceuticals by 7.1% in the second quarter. Hudson Bay Capital Management LP now owns 825,004 shares of the company's stock valued at $957,000 after purchasing an additional 55,004 shares during the period. 71.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABOS has been the subject of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Acumen Pharmaceuticals in a research report on Monday, July 6th. Wall Street Zen lowered Acumen Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, July 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $8.00.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.

The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source